James Hardie To Divest Fermacell In Europe To Holcim For €840 Mln Cash; Plans $250 Mln Buyback
James Hardie (JHX) agreed to sell its European Fermacell business to Holcim (HLB.F) for €840M. The deal is expected to close in H1 2027 and is projected to be accretive to margins. James Hardie also announced a $250M share buyback. Holcim expects the acquisition to be EPS accretive in year one and generate €22M in EBITDA synergies by year three.
How this was made

The 30-second read
Why it matters
The cash‑rich divestiture and buyback provide immediate financial relief and EPS uplift for Hardie, while Holcim gains market share in Europe.
Market read
Both companies face material corporate actions that can move their stocks; investors should assess the cash proceeds and buyback impact.
What to watch
Regulatory approvals and integration risks for Holcim may delay expected synergies.
Background
James Hardie focuses on exterior home solutions; Holcim is a Swiss building‑materials giant.
Ticker impact
James Hardie announced the sale of its European Fermacell business for €840 million and a $250 million share buyback, causing a 1.9% pre‑market price rise.
Short‑term upside as investors price in cash proceeds and buyback support.
Large cash transaction and immediate share repurchase signal financial strength and likely boost to EPS.
Market effects
Strengthens the building‑materials sector outlook by consolidating walling products in Europe.
European construction material markets may see tighter competition as Holcim expands.
Highlights continued M&A activity in the global building‑materials industry.
Counterpoint
The divestiture could signal James Hardie's retreat from a growth market, potentially weakening its long‑term positioning.
Key entities
- CompanyJames Hardie Industries PLC
Seller of Fermacell, initiator of $250 M buyback.
- CompanyHolcim AG
Acquirer of Fermacell, projecting synergies.
